# Phio Pharmaceuticals Corp. (PHIO)

Source: https://www.quantisnow.com/company/PHIO
Generated: 2026-11-09T01:30:10.077Z

- Ticker: PHIO
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- SEC CIK: 0001533040
- Website: phiopharma.com

## About

Phio Pharmaceuticals Corp., a biotechnology company, develops immuno-oncology therapeutics in the United States. It offers INTASYL therapeutic platform focuses on silencing tumor-induced suppression of the immune system. The company develops PH-762, which targets the checkpoint protein PD-1 that prevent T cells from attacking various cells for used in adoptive cell transfer (ACT); PH-804 that targets the suppressive immune receptor TIGIT, which is a checkpoint protein present on T cells and natural killer cells for used in ACT; and PH-790 which targets PD-L1 protein that prevent cancer cells from inactivating T cells and attack the cancer. It has collaboration with AgonOx, Inc. on clinical development of novel immunotherapy drugs targeting key regulators of the immune response to cancer. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.

## Latest PHIO news and filings

- 2026-11-06 14:05 UTC [Phio Pharmaceuticals Announces Invitation for Oral Presentation at 41st Annual SITC Meeting (Society for Immunotherapy of Cancer)](https://www.quantisnow.com/insight/phio-pharmaceuticals-announces-invitation-for-oral-presentation-at-41st-annual-6778242)
- 2026-11-05 21:14 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Phio Pharmaceuticals Corp.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-phio-pharmaceuticals-corp-6776575)
- 2026-11-05 21:12 UTC [SEC Form 8-K] [Phio Pharmaceuticals Corp. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/phio-pharmaceuticals-corp-filed-sec-form-8-k-results-of-operations-6776534)
- 2026-11-05 21:05 UTC [Earnings] [Phio Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Update as It Advances PH-762 Toward Phase 2b Study Initiation](https://www.quantisnow.com/insight/phio-pharmaceuticals-reports-third-quarter-2026-financial-results-and-business-6776191)
- 2026-10-19 13:53 UTC [Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series](https://www.quantisnow.com/insight/phio-pharmaceuticals-announces-participation-in-the-renmark-financial-communications-live-6750260)
- 2026-10-13 12:41 UTC [SEC Form 8-K] [SEC Form 8-K filed by Phio Pharmaceuticals Corp.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-phio-pharmaceuticals-corp-6744422)
- 2026-10-13 11:00 UTC [Phio Pharmaceuticals Announces Successful Completion of First Commercial-Scale cGMP Batch of PH-762 Drug Substance](https://www.quantisnow.com/insight/phio-pharmaceuticals-announces-successful-completion-of-first-commercial-scale-cgmp-batch-6744052)
- 2026-10-12 12:35 UTC [Conference Announcement] [OTC Markets Group Announces Third Annual Global Markets Forum Presentations Now Available On Demand](https://www.quantisnow.com/insight/otc-markets-group-announces-third-annual-global-markets-forum-presentations-6743550)
- 2026-10-06 11:00 UTC [Conference Announcement] [Phio Pharmaceuticals to Present at The Global Markets Virtual Forum October 8, 2026](https://www.quantisnow.com/insight/phio-pharmaceuticals-to-present-at-the-global-markets-virtual-forum-6738058)
- 2026-10-05 12:35 UTC [Conference Announcement] [OTC Markets Group Announces Agenda for Third Annual Global Markets Forum, October 7th & 8th](https://www.quantisnow.com/insight/otc-markets-group-announces-agenda-for-third-annual-global-markets-6736145)
- 2026-10-05 11:00 UTC [Conference Announcement] [Phio Pharmaceuticals to Present at the National Investment Banking Association (NIBA) 153rd Conference](https://www.quantisnow.com/insight/phio-pharmaceuticals-to-present-at-the-national-investment-banking-association-6735871)
- 2026-09-30 20:01 UTC [Insider Buy] [Director Plott Ronald Todd bought $10,350 worth of shares (10,000 units at $1.03), increasing direct ownership by 31% to 42,000 units (SEC Form 4)](https://www.quantisnow.com/insight/director-plott-ronald-todd-bought-10350-worth-of-shares-10000-6730532)
- 2026-09-29 20:01 UTC [SEC Form 4] [Chairman, Pres. & CEO Bitterman Robert J was granted 400,000 shares, increasing direct ownership by 110% to 764,871 units (SEC Form 4)](https://www.quantisnow.com/insight/chairman-pres-ceo-bitterman-robert-j-was-granted-400000-shares-6729143)
- 2026-09-29 20:01 UTC [SEC Form 4] [Chief Financial Officer Carson Lisa Cabott was granted 108,000 shares, increasing direct ownership by 133% to 189,112 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-financial-officer-carson-lisa-cabott-was-granted-108000-shares-6729141)
- 2026-09-29 20:01 UTC [SEC Form 4] [Director Plott Ronald Todd was granted 17,000 shares, increasing direct ownership by 113% to 32,000 units (SEC Form 4)](https://www.quantisnow.com/insight/director-plott-ronald-todd-was-granted-17000-shares-increasing-direct-6729140)
- 2026-09-28 20:33 UTC [SEC Form S-8] [SEC Form S-8 filed by Phio Pharmaceuticals Corp.](https://www.quantisnow.com/insight/sec-form-s-8-filed-by-phio-pharmaceuticals-corp-6727891)
- 2026-09-28 20:01 UTC [SEC Form 8-K] [Phio Pharmaceuticals Corp. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits](https://www.quantisnow.com/insight/phio-pharmaceuticals-corp-filed-sec-form-8-k-leadership-update-submission-6727623)
- 2026-09-25 20:01 UTC [SEC Form 4] [SEC Form 4 filed by Phio Pharmaceuticals Corp.](https://www.quantisnow.com/insight/sec-form-4-filed-by-phio-pharmaceuticals-corp-6726414)
- 2026-09-23 20:01 UTC [Insider Buy] [Chairman, Pres. & CEO Bitterman Robert J bought $2,058 worth of shares (2,000 units at $1.03), increasing direct ownership by 0.55% to 364,871 units (SEC Form 4)](https://www.quantisnow.com/insight/chairman-pres-ceo-bitterman-robert-j-bought-2058-worth-of-6724104)
- 2026-09-23 11:00 UTC [Phio Pharmaceuticals to Present Clinical Development Update and Upcoming Catalysts at Life Sciences Future 2026 Conference](https://www.quantisnow.com/insight/phio-pharmaceuticals-to-present-clinical-development-update-and-upcoming-catalysts-6723579)
- 2026-09-16 20:01 UTC [Insider Buy] [Director Bradford Patricia A bought $12,360 worth of shares (12,000 units at $1.03), increasing direct ownership by 26% to 57,651 units (SEC Form 4)](https://www.quantisnow.com/insight/director-bradford-patricia-a-bought-12360-worth-of-shares-12000-6717399)
- 2026-09-15 20:00 UTC [SEC Form 4] [Chairman, Pres. & CEO Bitterman Robert J covered exercise/tax liability with 68,550 shares, decreasing direct ownership by 16% to 362,871 units (SEC Form 4) to satisfy withholding tax](https://www.quantisnow.com/insight/chairman-pres-ceo-bitterman-robert-j-covered-exercisetax-liability-with-6715984)
- 2026-09-15 20:00 UTC [SEC Form 4] [Chief Financial Officer Carson Lisa Cabott covered exercise/tax liability with 12,888 shares, decreasing direct ownership by 14% to 81,112 units (SEC Form 4) (withholding obligation)](https://www.quantisnow.com/insight/chief-financial-officer-carson-lisa-cabott-covered-exercisetax-liability-with-6715983)
- 2026-09-14 12:59 UTC [SEC Form 8-K] [Phio Pharmaceuticals Corp. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/phio-pharmaceuticals-corp-filed-sec-form-8-k-other-events-financial-6713937)
- 2026-09-14 11:00 UTC [Phio Announces Key Development Milestone for PH-762 with FDA Submission Supporting Next Stage of Clinical Development in Cutaneous Squamous Cell Carcinoma](https://www.quantisnow.com/insight/phio-announces-key-development-milestone-for-ph-762-with-fda-submission-6713667)
- 2026-09-11 13:00 UTC [Conference Announcement] [Phio Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference](https://www.quantisnow.com/insight/phio-pharmaceuticals-to-participate-in-the-hc-wainwright-28th-annual-6712606)
- 2026-08-20 12:30 UTC [Insider Buy] [Director Plott Ronald Todd bought $17,100 worth of shares (15,000 units at $1.14) (SEC Form 4)](https://www.quantisnow.com/insight/director-plott-ronald-todd-bought-17100-worth-of-shares-15000-6689557)
- 2026-08-19 20:01 UTC [Insider Buy] [Chairman, Pres. & CEO Bitterman Robert J bought $10,600 worth of shares (10,000 units at $1.06), increasing direct ownership by 2% to 431,421 units (SEC Form 4)](https://www.quantisnow.com/insight/chairman-pres-ceo-bitterman-robert-j-bought-10600-worth-of-6688243)
- 2026-08-11 11:00 UTC [Phio Pharmaceuticals Secures U.S. Notice of Allowance for INTASYL Composition Selectively Targeting BRD4 Protein with Compound PH-894](https://www.quantisnow.com/insight/phio-pharmaceuticals-secures-us-notice-of-allowance-for-intasyl-composition-6674874)
- 2026-08-06 20:16 UTC [SEC Form 8-K] [Phio Pharmaceuticals Corp. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/phio-pharmaceuticals-corp-filed-sec-form-8-k-results-of-operations-6669291)
- 2026-08-06 20:13 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Phio Pharmaceuticals Corp.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-phio-pharmaceuticals-corp-6669171)
- 2026-08-06 20:05 UTC [Leadership Update] [Phio Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update](https://www.quantisnow.com/insight/phio-pharmaceuticals-reports-second-quarter-2026-financial-results-and-business-6668789)
- 2026-07-30 20:01 UTC [SEC Form 3] [SEC Form 3 filed by new insider Plott Ronald Todd](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-plott-ronald-todd-6655930)
- 2026-07-22 16:30 UTC [Correction to Announcement Regarding Phio Pharmaceuticals Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series](https://www.quantisnow.com/insight/correction-to-announcement-regarding-phio-pharmaceuticals-participation-in-the-renmark-6644975)
- 2026-07-22 11:00 UTC [Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series](https://www.quantisnow.com/insight/phio-pharmaceuticals-announces-participation-in-the-renmark-financial-communications-live-6644543)
- 2026-07-21 11:07 UTC [SEC Form 8-K] [Phio Pharmaceuticals Corp. filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/phio-pharmaceuticals-corp-filed-sec-form-8-k-leadership-update-other-6643156)
- 2026-07-21 11:00 UTC [Leadership Update] [Phio Pharmaceuticals Announces Appointment of Dr. R. Todd Plott to the Board of Directors](https://www.quantisnow.com/insight/phio-pharmaceuticals-announces-appointment-of-dr-r-todd-plott-to-6643145)
- 2026-07-15 11:00 UTC [Phio Pharmaceuticals Announces Patent Milestone with Multiple Notices of Allowance and Grant Decision](https://www.quantisnow.com/insight/phio-pharmaceuticals-announces-patent-milestone-with-multiple-notices-of-allowance-6637532)
- 2026-06-29 20:02 UTC [Insider Buy] [Chairman, Pres. & CEO Bitterman Robert J bought $9,900 worth of shares (10,000 units at $0.99), increasing direct ownership by 2% to 421,421 units (SEC Form 4)](https://www.quantisnow.com/insight/chairman-pres-ceo-bitterman-robert-j-bought-9900-worth-of-6618851)
- 2026-06-26 12:35 UTC [Conference Announcement] [Life Sciences Virtual Investor Forum Presentations Now Available for On-Demand Viewing](https://www.quantisnow.com/insight/life-sciences-virtual-investor-forum-presentations-now-available-for-on-demand-6616806)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/PHIO
- Earnings history: https://www.quantisnow.com/earnings/PHIO
- Dividend history: https://www.quantisnow.com/dividends/PHIO
- Insider transactions: https://www.quantisnow.com/insiders/PHIO
- Options chain: https://www.quantisnow.com/options/PHIO
- SEC 8-K filings only: https://www.quantisnow.com/company/PHIO/8-k
- RSS and alerts for PHIO: https://www.quantisnow.com/docs/rss-feeds.md